Filing Flows

Filing Flows › Health Care › Organogenesis Holdings (ORGO)

Organogenesis Holdings (ORGO) earnings and revenue breakdown

Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Organogenesis Holdings (ORGO) Q3 2026 earnings results →

Q3 2026 Revenue down 70% year over year to $45.5M · 65¢ of every $1 of revenue lost · operating margin -64.9%

Organogenesis Holdings made $45.5M in Q3 2026 (-70% Y/Y). Operating margin -64.9%, net loss $29.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.

Revenue$45.5M
Year over year-70%
Operating margin-64.9%
Net earnings−$29.6M
Operating cash flow−$18.6M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $45.5M in Q3 2026, down 70% year over year and up 4% from the previous quarter.

Operating costs exceeded revenue by $29.5M, an operating margin of -64.9%. Total costs fell 42% while revenue fell 70%. The quarter ended with a net loss of $29.6M, narrower than the previous quarter's $96.3M loss.

Operating cash flow was −$18.6M. Non-cash charges added back $3.9M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$20.1M.

Quarterly history

Organogenesis Holdings revenue by quarterOrganogenesis Holdings revenue by quarter$86.7MQ1 2025$101MQ2 2025$151MQ3 2025$226MQ4 2025$37.2MQ1 2026$43.8MQ2 2026$45.5MQ3 2026
Organogenesis Holdings net earnings by quarterOrganogenesis Holdings net earnings by quarter−$18.8MQ1 2025−$9.4MQ2 2025$21.6MQ3 2025$43.7MQ4 2025−$53.2MQ1 2026−$96.3MQ2 2026−$29.6MQ3 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q3 202610-QNov 5, 2026$45.5M-70%-64.9%−$29.6M−$18.6M
Q2 202610-QAug 6, 2026$43.8M-57%-116.5%−$96.3M−$31.7M
Q1 202610-QMay 7, 2026$37.2M-57%-185.1%−$53.2M$21.1M
Q4 202510-KFeb 26, 2026$226M+78%28.1%$43.7M$39.4M
Q3 202510-QNov 6, 2025$151M+31%13.7%$21.6M$3.1M
Q2 202510-QAug 7, 2025$101M-22%-12.5%−$9.4M−$32.9M
Q1 202510-QMay 8, 2025$86.7M-21%-30.9%−$18.8M−$19.9M

Charts

Organogenesis Holdings: revenue growth, year over year and quarter over quarterOrganogenesis Holdings: revenue growth, year over year and quarter over quarterY/YQ/Q-21%Q1 2025-22%+17%Q2 2025+31%+49%Q3 2025+78%+50%Q4 2025-57%-83%Q1 2026-57%+18%Q2 2026-70%+4%Q3 2026
Latest (Q3 2026): Y/Y -70%, Q/Q +4%.
Organogenesis Holdings: where the cash came from (+) and went (−), TTM to Q3 2026Organogenesis Holdings: where the cash came from (+) and went (−), TTM to Q3 2026Cash drawn (+) / kept (−)$37.4MOther financing−$26.9MNet borrowing (+) / repaid (−)−$10.9MCapital spending−$10.4MOperating cash flow$10.3MOther investing$3.6MTaxes on employees’ shares−$3.1M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Organogenesis Holdings: profit against cash, quarter by quarterOrganogenesis Holdings: profit against cash, quarter by quarterNet incomeOperating cash flow$7.7M$10.9MQ4 2024−$18.8M−$19.9MQ1 2025−$9.4M−$32.9MQ2 2025$21.6M$3.1MQ3 2025$43.7M$39.4MQ4 2025−$53.2M$21.1MQ1 2026−$96.3M−$31.7MQ2 2026−$29.6M−$18.6MQ3 2026
Latest (Q3 2026): Net income −$29.6M, Operating cash flow −$18.6M.
Organogenesis Holdings: diluted shares by fiscal yearOrganogenesis Holdings: diluted shares by fiscal year111MFY2020134MFY2021132MFY2022133MFY2023132MFY2024130MFY2025
+17.0% since FY2020: more shares outstanding (issuance, stock pay).
Organogenesis Holdings in its industry: growth against margin (225 companies, SIC 2834)Organogenesis Holdings in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVINUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBIRDOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMORGO (-70%, -65%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Organogenesis Holdings

Organogenesis Holdings Inc. is a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com .

In its own words, from its 8-K, filed Aug 6, 2026.

Organogenesis Holdings against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -70% against the peers' median +7%. Operating margin: -64.9% against the peers' median 20.4%.

CompanyQuarterRevenueY/YOp. margin
ORGO Organogenesis HoldingsQ3 2026$45.5M-70%-64.9%
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Organogenesis Holdings 10-Q on SEC EDGAR · CIK 1661181 · Pharmaceutical Preparations

Guidance and outlook

Organogenesis Holdings: what its forward-looking statements are about (10-Q filed 2026-11-05)Organogenesis Holdings: what its forward-looking statements are about (10-Q filed 2026-11-05)Other5Demand3The economy1Products1Costs1Capital spending1Financing1
13 statements; tone -0.15 (−1 all cautious, +1 all confident); 3 hedged.
Organogenesis Holdings: outlook statements against the filing beforeOrganogenesis Holdings: outlook statements against the filing beforeConfident2Cautious4

13F: who owns ORGO and who is buying

Largest holders of ORGO (13F)Largest holders of ORGO (13F)Morgan Stanley$28.5MVanguard Group$25.7MSoleus Capital Management, L.P.$24.6MBlackRock$17.6MDimensional Fund Advisors LP$7.4MAQR Capital Management LLC$7.3MVanguard Capital Management LLC$7.1MD. E. Shaw$7.0MGeode Capital Management, LLC$4.7MVanguard Portfolio Management LLC$3.9M
Funds' net buying of ORGO by quarter (13F)Funds' net buying of ORGO by quarter (13F)$7.6M2024-09−$4.9M2024-12$10.5M2025-03$16.8M2025-06−$3.3M2025-09−$2.6M2025-12−$14.8M2026-03$15.4M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on ORGO

History

Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results

Compare ORGO with

中文版：Organogenesis Holdings（ORGO）财报

Español · Français